-

$undefined

N/A

(N/A)

Cue Biopharma NASDAQ:CUE Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Location: 21 Erie St, Massachusetts, 02139-4260, US | Website: www.cuebiopharma.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

60.71M

Cash

32.42M

Avg Qtr Burn

-9.565M

Short % of Float

1.74%

Insider Ownership

0.55%

Institutional Own.

18.59%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CUE-102 Details Wilms' Tumor 1 (WT1), Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-101 (IL-2) +/- pembrolizumab Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s, Human papillomavirus	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.